Park Square Financial Group LLC Invests $44,000 in Edwards Lifesciences Co. (NYSE:EW)

Park Square Financial Group LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 600 shares of the medical research company’s stock, valued at approximately $44,000.

Several other hedge funds also recently made changes to their positions in EW. Janney Montgomery Scott LLC grew its position in shares of Edwards Lifesciences by 0.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 43,095 shares of the medical research company’s stock worth $3,190,000 after acquiring an additional 302 shares in the last quarter. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $266,000. Blue Trust Inc. grew its position in shares of Edwards Lifesciences by 35.6% in the 4th quarter. Blue Trust Inc. now owns 10,914 shares of the medical research company’s stock worth $808,000 after acquiring an additional 2,865 shares in the last quarter. Mount Yale Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after acquiring an additional 162 shares in the last quarter. Finally, Strategic Blueprint LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $203,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, May 16th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a research report on Friday, April 25th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Barclays boosted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $80.20.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. This represents a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,692 shares of company stock valued at $4,822,074 over the last three months. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 0.6%

Shares of Edwards Lifesciences stock opened at $76.64 on Thursday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business has a fifty day simple moving average of $73.09 and a 200-day simple moving average of $72.25. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.66 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.